Chakka et al.
935
H+. The neutralized solution was filtered and evaporated to
dryness in vacuo to give a white solid. The crude product
was purified by column chromatography on silica gel
(EtOAc–methanol–water, 6:3:1) to give the title compound
as a white crystalline solid (0.39 g, 82%); mp 151–153 °C
(EtOH). [α]2D3 –100 (c 1.15, D2O). 1H NMR (400 MHz,
D2O) δ: 4.81 (1H, d, J1,2 = 3.7 Hz, H-1), 4.36 (1H, d,
J1 ′,2 ′ = 9.5 Hz, H-1′), 4.07 (1H, dd, J2,3 ≈ J3,4 ≈ 9.9 Hz, H-
3), 4.00–3.94 (4H, m, H-4′, H-5′, H-6a, H-6b), 3.77 (1H,
dd, J2 ′,3 ′ = 9.6 Hz, H-2′), 3.76 (1H, dd, J5,6a = 6.9 Hz,
J6a,6b = 12.2 Hz, H-6a′), 3.73–3.66 (3H, m, H-5, H-3′, H-
6b′), 3.62 (1H, dd, H-2), 3.40 (3H, s, OMe), 2.65 (1H, dd,
J4,5 = 10.2 Hz, H-4). 13C NMR (400 MHz, D2O) δ: 102.06
(C-1), 91.84 (C-1′), 82.23 (C-5′), 76.53 (C-3′), 75.18 (C-2),
73.77 (C-4′), 71.22 (C-5), 71.09 (C-2′), 70.52 (C-3), 64.22
(C-6′), 63.96 (C-6), 57.84 (OMe), 52.61 (C-4). MALDI-
TOF-MS calcd. for C13H24O10S2: 404.1; found: 427.3 (M +
Na)+. Anal. calcd. for C13H24O10S2: C 38.61, H 5.98; found:
C 38.55, H 6.00.
Methyl-4-Se-(-D-galactopyranosyl-1′-thio)-4-seleno-␣-D-
glucopyranoside (2)
The blocked selenosulfide 9 (2.0 g, 2.15 mmol) was
treated with 1 mol/L methanolic sodium methoxide (6 mL)
at room temperature for 1 h in dry methanol (80 mL). The
reaction mixture was then adjusted to pH 6.4 with Rexyn
101 H+. The solution was filtered and evaporated to dryness
in vacuo to give a white solid. The crude product was puri-
fied by column chromatography on silica gel (EtOAc–meth-
anol–water, 6:3:1); the title compound was obtained as a
white crystalline solid (0.75 g, 77%); mp 122–124 °C
(EtOH). [α]2D3 –114 (c 2.75, D2O). 1H NMR (400 MHz,
D2O) δ: 4.63 (1H, d, J1,2 = 3.7 Hz, H-1), 4.37 (1H, d, J1′,2′
=
8.3 Hz, H-1′), 4.03 (1H, dd, J2,3 ≈ J3,4 = 9.6 Hz, H-3), 4.01–
3.93 (4H, m, H-5, H-4′, H-6a, H-6b), 3.79–3.65 (5H, m,
H-5′, H-6a′, H-6b′, H-2′, H-3′), 3.62 (1H, dd, H-2), 3.39
(3H, s, OMe), 2.94–2.83 (1H, second order multiplet, H-4).
13C NMR (400 MHz, D2O) δ: 102.15 (C-1), 90.56 (C-1′),
82.20 (C-5′), 76.39 (C-3′), 75.19 (C-2), 74.31 (C-4′), 72.68
(C-5), 71.39 (C-2′), 71.11 (C-3), 64.94 (C-6′), 63.94 (C-6),
57.87 (OMe), 48.62 (C-4). MALDI-TOF-MS calcd. for
C13H24O10SSe: 452.0; found: 475.1 (M + Na)+. Anal. calcd.
for C13H24O10SSe: C 34.59, H 5.36; found: C 34.27, H 5.50.
Methyl 2,3,6-tri-O-benzoyl-4-Se-(2′,3′,4′,6′-tetra-O-
acetyl--D-galactopyranosyl-1′-thio)-4-seleno-␣-D-
glucopyranoside (9) and methyl 2,3,6-tri-O-benzoyl-4-
seleno-␣-D-glucopyranoside diselenide (10)
Methyl 4-seleno--D-glucopyranoside diselenide (11)
The protected (4→4′) diselenide 10 (0.725 g, 0.62 mmol)
was treated with 1 mol/L methanolic sodium methoxide
(4 mL) at room temperature for 2.5 h in dry methanol
(40 mL). The reaction mixture was then neutralized to
pH 6.2 with Rexyn 101 H+. The neutralized solution was fil-
tered and evaporated to dryness in vacuo to give a yellow
solid. The crude product was purified by column chromatog-
raphy on silica gel (EtOAc–methanol–water, 6:3:1) to give
the title compound as a yellow crystalline solid (0.31 g,
98%); mp 95–97 °C. [α]2D1 –77 (c 0.4, D2O). 1H NMR
(400 MHz, D2O) δ: 4.83 (1H, d, J1,2 = 3.4 Hz, H-1), 3.99
(2H, d, H-6a, H-6b), 3.85 (1H, dd, J2,3 = 9.7 Hz, H-3), 3.72
(1H, ddd, J5,6a = 2.9 Hz, H-5), 3.64 (1H, dd, H-2), 3.78
(3H, s, OCH3), 2.85 (1H, dd, J3,4 = 10.7 Hz, H-4). MALDI-
TOF-MS calcd. for C14H26O10Se2: 514.0; found: 537.2 (M +
Na)+. Anal. calcd. for C14H26O10Se2: C 32.82, H 5.12;
found: C 33.09, H 5.37.
To a mixture of thiosulfonate 5 (2.20 g, 4.98 mmol) and
selenol 8 (3.68 g, 6.29 mmol) in EtOAc (55 mL) was added
phase-transfer catalyst, tetrabutylammonium hydrogensulfate
(2.56 g, 7.5 mmol), and saturated aqueous sodium hydro-
gencarbonate (40 mL). The reaction mixture was stirred at
room temperature under nitrogen overnight and diluted with
EtOAc (150 mL). The organic layer was then washed with
saturated sodium chloride solution (2 × 50 mL) followed by
water (2 × 100 mL). The organic layer was dried over anhy-
drous sodium sulfate and evaporated. The crude product was
then purified by column chromatography on silica gel
(EtOAc–hexane, 1:2.5). The title compound 9 was obtained
as a colorless amorphous solid (2.4 g, 52%) and the pro-
tected (4→4′) diselenide 10, a by-product, was obtained as a
yellow solid (1.43 g, 38% with respect to selenol 8). Com-
1
pound 9: [α]2D3 +66 (c 0.5, CHCl3). H NMR (400 MHz,
CDCl3) δ: 8.10–7.94 (6H, 3d, 3 × OBz ortho H), 7.62–7.32
(9H, m, 3 × OBz meta + para H), 6.21 (1H, dd, J2,3
=
9.2 Hz, J3,4 = 10.7 Hz, H-3), 5.51 (1H, d, J3 ′,4 ′ = 3.4 Hz,
J4 ′,5 ′ = 0.0 Hz, H-4′), 5.30 (1H, dd, J1 ′,2 ′ = 10.0 Hz, H-2′),
5.22 (1H, dd, J1,2 = 3.6 Hz, H-2), 5.20 (1H, d, H-1), 5.13
Acknowledgment
We are grateful to the Natural Sciences and Engineering
Research Council of Canada (NSERC) for financial support.
(1H, dd, J2 ′,3 ′ = 10.0 Hz, H-3′), 4.89 (1H, broad dd, J6a,6b
=
12.1 Hz, H-6a), 4.73 (1H, dd, J5,6b = 2.0 Hz, H-6b), 4.65
(1H, broad d, H-1′), 4.57 (1H, ddd, H-5), 4.40–4.28 (3H,
br m, H-5′, H-6a′, H-6b′), 3.48 (3H, s, OMe), 3.30 (1H, dd,
H-4), 2.21, 2.02, 2.00, 1.99 (12H, 4s, 4 × OAc). 13C NMR
(400 MHz, CDCl3) δ: 170.45–169.54 (CO, 4 × OAc),
166.20, 165.81, 165.57 (CO, 3 × OBz), 133.29–128.37
(18C, 3 × Ph), 97.35 (C-1), 87.0 (C-1′), 74.60 (C-5′), 73.35
(C-2), 71.77 (C-3′), 69.86 (C-3), 68.26 (C-5), 66.85 (C-
2′,4′), 64.39 (C-6), 60.36 (C-6′), 55.69 (OMe), 42.60 (C-4),
20.80–20.60 (Me, 4 × OAc). MALDI-TOF-MS calcd. for
C42H44O17SSe: 932.1; found: 955.5 (M + Na)+. Anal. calcd.
for C42H44O17SSe: C 54.14, H 4.76; found: C 54.03, H 4.90.
Compound 10: This product was found to have identical
physical constants and NMR data to those previously re-
ported (31).
References
1. A. Varki, R. Cummings, J. Esko, H. Freeze, G. Hart, and J.
Marth (Editors). Essentials of glycobiology. Cold Spring Har-
bor Laboratory Press, Cold Spring Harbor, New York. 1999.
2. M.E. Taylor and K. Drickamer. Introduction to glycobiology.
Oxford University Press, New York. 2003.
3. A. Helenius and M. Aebi. Science, 291, 2364 (2001).
4. (a) R.A. Dwek, T.D. Butters, F.M. Platt, and N. Zitzmann. Na-
ture Rev. Drug Discovery, 1, 65 (2002); (b) R.A. Dwek. Chem.
Rev. 96, 683 (1996).
5. V.H. Lillelund, H.H. Jensen, X. Liang, and M. Bols. Chem.
Rev. 102, 515 (2002).
6. N. Asano. Glycobiology, 13, 93R (2003).
© 2005 NRC Canada